Abstract

You have accessJournal of UrologyInfections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia II1 Apr 2017MP11-13 RISK FACTOR ASSESSMENT FOR FLUOROQUINOLONE RESISTANT E. COLI (FRE) IN BOWEL FLORA IS NOT SUFFICIENTLY DISCRIMINATORY: THE CASE FOR A PRE-BIOPSY RECTAL SWAB IN ALL PATIENTS. Michael Holmes, Ray Littler, Megan Lyons, Lisa Smit, Glen Devcich, Adam Davies, John leyland, and Chris Mansell Michael HolmesMichael Holmes More articles by this author , Ray LittlerRay Littler More articles by this author , Megan LyonsMegan Lyons More articles by this author , Lisa SmitLisa Smit More articles by this author , Glen DevcichGlen Devcich More articles by this author , Adam DaviesAdam Davies More articles by this author , John leylandJohn leyland More articles by this author , and Chris MansellChris Mansell More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.414AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Infective complications post transrectal ultrasound guided (TRUS) prostate biopsy appear to be increasing, probably linked to a rising prevalence of FRE in the bowel flora. Several authors have suggested potential patient factors which may increase the risk of FRE carriage or sepsis post TRUS prostate biopsy . National guidelines have suggested screening only high risk patients for FRE. We sought in a prospective study to assess the prevalence of FRE in our patients and whether previously identified patient factors were related to this. Can we identify a high risk group for FRE and disregard the rest? METHODS A transrectal swab, screening for FRE, was taken prior to biopsy. Antibiotic prophylaxis was 1 gram p.o. of ciprofloxacin prior to and 500mg after biopsy. Targeted antibiotics were used if a FRE was identified. Information was collected on: 1. Previous number of TRUS prostate biopsies, 2. Overseas travel within the last 6 months and if to a developing country, 3. Diarrhoea while away, 4. Overseas travel at any stage and if to a developing country, 5. Antibiotic use within the last six months, 6. Diabetes and 7. Inflammatory bowel disease. Naive Bayes, Logistic Regression, and Random Forest classifiers were used to build predictive models. A leave-one-out validation was used to generate class probabilities to quantify expected performance. RESULTS Rectal swabs were performed in 1135 of 1216 prostate biopsies. FRE was detected in 95 (8.4%) of which 16 were extended spectrum beta lactamase (ESBL) E.coli. The prevalence of patient risk factors are shown in Table 1. Travel to a developing country within 6 months, ever, and diarrhoea while away were associated with FRE carriage (p<0.05). 327 patients had travelled to a developing country of whom 53 carried FRE. A naive classifier based on this would mean screening 30% to detect 50% of FRE carriers. Using leave-one-out the best classifier meant 80% of FRE was detected if 87% of patients were screened. CONCLUSIONS Travel to a developing country was associated with an increased risk of carrying FRE. However no model could be constructed that would allow screening of a small enough high risk group that was sufficiently useful. Based on this all patients should be screened for FRE prior to a TRUS prostate biopsy. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e141 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Michael Holmes More articles by this author Ray Littler More articles by this author Megan Lyons More articles by this author Lisa Smit More articles by this author Glen Devcich More articles by this author Adam Davies More articles by this author John leyland More articles by this author Chris Mansell More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call